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Abstract 
Osteoporosis can occur at any age. In premenopausal osteoporosis, full 
achievement of peak bone mass may be curtailed, and accelerated bone loss may 
occur in young adulthood. Premenopausal osteoporosis may be associated with 
chronic glucocorticoid therapy, prolonged amenorrhea, anorexia nervosa, 
rheumatoid arthritis, and diseases that affect calcium and vitamin D metabolism. 
Lesser degrees of bone loss may be associated with common conditions such as 
dieting, low calcium intake, smoking, and oligomenorrhea. 
Due to a paucity of prospective studies on screening and treatment in younger age 
groups, few practice recommendations exist to guide management of osteoporosis 
in young adults. We review the most important clinical concerns in 
premenopausal osteoporosis, including measurement of bone mass, normal bone 
accrual, risk factors for premature bone loss, clinical outcomes and management 
issues. We emphasize clinically relevant information for primary care physicians 
who are usually the first to encounter premenopausal patients with risk factors for 
early bone loss. 
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CLINICAL CONSIDERATIONS IN PREMENOPAUSAL 
OSTEOPOROSIS 
Introduction 
Although low bone mass and accelerated bone loss can occur early in life, 
osteoporosis is usually considered a disorder of postmenopausal women. The 
most serious consequences of osteoporosis occur in this age group, and treatment 
outcomes may be poor after a fracture late in life. Hip fractures cause the most 
morbidity and mortality; hip fracture incidence in white women increases tenfold 
from 50.1 per 100,000 per year at ages 50-54, to 530.5 per I 00,000 per year at 
ages 70-741 Vertebral fractures and distal forearm (Colle's) fractures occur more 
commonly after menopause and are associated with a higher subsequent rate of 
h. fr t 2-4 1p ac ure. 
Certain groups of premenopausal women are at high risk of osteoporosis, 
including those with disease states or exogenous influences that promote 
accelerated bone loss. The 2001 NIH Consensus Development Panel on 
Osteoporosis Prevention, Diagnosis and Therapy specified peak bone mass in 
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children and secondary osteoporosis in young adults as important areas for future 
research. 5 At present, relatively little is known about early-onset osteoporosis, 
and no general practice recommendations exist to guide diagnosis and therapy. 
We present an overview of the most important clinical concerns in premenopausal 
osteoporosis, with the goal of increasing awareness of high-risk patients who 
often present first to primary care physicians. This review addresses 
measurement of bone mass, normal bone accrual, risk factors for premature bone 
loss, clinical outcomes and management issues in premenopausal women. 
Methods 
We searched the MEDLINE/PubMed database (1984 to August 2002) using the 
following MeSH terms: osteoporosis, premenopause (for articles on 
premenopausal osteoporosis); bone diseases, metabolic OR low bone mass OR 
bone density OR osteopenia, AND premenopause NOT osteoporosis (for articles 
on premenopausal osteopenia). We reviewed abstracts for all English language 
citations in peer reviewed journals and excluded references for the following 
reasons: studies that included perimenopausal and/or postmenopausal women 
only; studies with premenopausal women as a reference group/control only, 
without analysis and discussion of relevant outcomes in premenopausal patients; 
lack of osteoporosis-related health outcomes; purpose of study was to verify an 
experimental radiological diagnostic tool; insufficient length of study to assess 
significant change in outcome. 
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Our initial search yielded 287 articles on premenopausal osteoporosis of which 
176 articles were excluded, and 202 articles on osteopenia of which 126 were 
excluded; the remaining 185 articles were reviewed for relevance and quality. An 
additional 187 articles from supplementary searches and hand searches of 
reference lists were evaluated. Due to the broad scope of this review and the 
general paucity of prospective studies from our searches, we considered all study 
designs except case reports and diagnostic test verification studies. One author 
(MLG) used a checklist to evaluate the internal validity of scientific studies, 
systematic reviews and meta-analyses. 
Results 
Bone density in younger patients 
The NIH Consensus Panel 2000 adopted a definition of osteoporosis as a skeletal 
disorder characterized by compromised bone strength predisposing to an 
increased risk offracture.6 Bone strength is determined both by bone density and 
bone quality. 
Since fragility fractures are rare in young patients, they are usually not used as 
outcomes in studies of premenopausal bone loss, nor do they serve as the basis for 
diagnosis of early-onset osteoporosis. Instead, bone densitometry measurements 
are used as surrogate indicators of fracture risk. The relationship between bone 
mineral density (BMD) measures and fracture risk is unclear in premenopausal 
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women. In postmenopausal women, a strong relationship exists between bone 
mineral density and fracture risk, such that a 10% decrease in BMD confers a 1.6-
2.6 fold increased risk for spine and hip fracture 7 
MEASUREMENT OF BONE MASS IN YOUNGER PATIENTS 
Bone mineral density (BMD) is a two-dimensional, areal projection measurement 
defined as the average concentration of mineral per unit area, expressed in 
grams/cm2.8 It is usually measured by dual-energy x-ray absorptiometry (DXA), 
or by single-energy x-ray absorptiometry in some cases. 
BMD is reported using two scores based on standard deviation measurements: the 
Z score and the T score. The Z score compares the patient's BMD to the mean 
value in age-matched normal subjects. This is the most appropriate measure to 
use for children and young adults who have yet to achieve their lifetime peak 
bone mass. The T score compares the patient's BMD to the mean in a healthy 
young reference population, assumed to represent a standard for peak bone mass. 
Both scores may be adjusted for race and gender. AT score of -2.5 or lower 
meets World Health Organization criteria for osteoporosis.9 AT score between-
2.5 and -1 represents osteopenia; however, since fracture risk may vary widely 
based on age and other factors for patients with osteopenia, this categorization is 
oflimited clinical value8 
Several factors should be considered when assessing bone density during periods 
of longitudinal growth. First, bone density measurements obtained by DXA 
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reflect a two-dimensional rather than a three-dimensional projection and may 
inaccurately capture geometric changes or increases in bone size that occur during 
growth. Additionally, the two-dimensional DXA measure may suggest a falsely 
lower BMD in small-framed individuals, which could be particularly important in 
evaluating premenopausal women. Other techniques, such as quantitative 
computed tomography, measure bone volume (grams/cm3) and may better 
characterize changes in total bone mass that occur during growth; however, their 
use is limited due to cost and contrast dye exposure. Second, bone density and 
calcium accrual vary by site of measurement with a general trend toward earlier 
bone density accrual in the proximal femur and vertebral body with later accrual 
at other sites. 1° Finally, small changes in BMD may be due to the random 
variability in the DXA test; changes ofless than about 5.6% can often be due to 
precision error and should be interpreted cautiously. 8 
BMD is most often measured at the lumbar spine and proximal femur, because 
measures at these sites have been best validated against fracture in 
postmenopausal women. Discordance in BMD scores at these sites is common in 
young women, probably due to differing rates of bone accrual and loss. Bannick 
eta!. studied BMD values in 237 premenopausal women and reported that a 
difference in Z score of> I occurred between the spine and proximal femur in 20-
24% of women ages 20-29, and 32-46% of women ages 30-45. 11 Peripheral DXA 
measurements of the distal radius and calcaneus can be performed; however, these 
values may not correlate with spine and hip measures and do not predict hip 
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fractures as well as hip BMD.12 Until peripheral DXA has been further validated 
against fracture, abnormal peripheral measures should be followed up with 
additional measurements of the spine and/or hip to confirm a diagnosis of 
osteoporosis. 
ATTAINMENT OF PEAK BONE MASS 
Peak rates of calcium accrual occur earlier than age 30. Longitudinal studies have 
demonstrated that calcium utilization increases during early puberty 13 and the 
highest rates of calcium accrual may occur at a mean age of 12.5 in girls andl4 in 
boys. 14 After this period of rapid calcium accretion, a period of bone 
consolidation is thought to ensue between age 20 and 30. Calcium accrual rates 
change little during this period, but periosteal expansion (outer surface of bone) 
may be increasing10. These periosteal changes could theoretically confer greater 
structural integrity and would not be adequately detected by bone density 
measurements using DXA. One study found that the independent determinants of 
BMD during growth were Tanner stage in girls and weight in boys. 15 Due to the 
complex processes that occur during bone development, changes in bone mass in 
growing individuals may be difficult to interpret. Several investigators have 
begun to develop normative databases to more accurately define expected bone 
mineral density values for younger age ranges. 16• 17 
Factors influencing the attainment of peak bone mass have recently been 
reviewed. 18• 19 The precise age at which peak bone mass occurs is unknown. 
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Population-based, cross-sectional studies indicate that women may attain peak 
bone mass in their 20s at the proximal femur and near age 30 at the spine and 
forearm 20• 21 ; however, age of attainment could vary in normal individuals.22 A 
cross-sectional study of 265 premenopausal white females ages eight to 50 years 
showed that most of the bone mass at multiple skeletal sites will be accumulated 
by late adolescence.10 
Multiple factors affect attainment of peak bone mass including genetic 
background, nutritional influences and activity level. Twin and family studies 
suggest that 50-80% of the variance in bone mass is heritable.23• 24 A strong 
association has been noted between bone densities in mother/daughter pairs, 
which may be apparent before the daughter has begun puberty. 25-27 
BONE MASS IN PREMENOPAUSE 
Sowers and Galuska published a comprehensive review of the epidemiology of 
bone mass in premenopausal women in 1993.28 They reported conflicting 
findings regarding BMD status after the attainment of peak bone mass and before 
the onset of menopause. Most cross-sectional studies from the 1980s and early 
1990s reported stable BMD in the premenopausal period. However, the majority 
of prospective and cross-sectional studies since 1994 have reported a small degree 
of loss ( <0.5% per year) during this time period, especially at the proximal femur, 
and more often in women with subclinical or clinical ovulation disturbances or 
menopausal symptoms (Table 1).29' 32 
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Risk factors for premenopausal osteoporosis 
Risk factors for low bone mass and osteoporotic fractures have been well studied 
in peri- and postmenopausal patients33-36 Few studies have comprehensively 
examined predictors in younger patients. Moreira-Kulak et a!. studied Ill pre-
and perimenopausal women under 55 years of age with T scores of -2.0 or below 
at one or more anatomic sites, who were referred to a tertiary center for metabolic 
bone disorders.37 Seventy-three of these women (66%) had an identifiable cause 
of bone loss. Conditions associated with estrogen deficiency, and use of 
glucocorticoid therapy were the most common known causes of osteoporosis. 
However, thirty-eight women (34%), 21 of whom were premenopausal, had no 
identifiable cause of low bone mass. Peris eta!. studied 52 premenopausal I 
osteoporotic women ages 20-51 whom were referred to an outpatient 
rheumatology clinic for osteoporosis evaluation and similarly found that 56% (29 
patients) had no identifiable predisposing condition?8 
Tudor-Locke and McColl recently reviewed risk factors for variation in bone 
status in premenopausal women ages 20-50.39 Nonmodifiable risk factors include 
genetic influences, and race and ethnicity. Potentially modifiable categories of 
risk include hormonal and nutritional factors, physical activity, medications and 
smoking. Certain disease states known to be associated with early bone loss can 
be secondary causes of osteoporosis. 
GENETIC INFLUENCES 
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Twin and family study have shown that genetic factors play an important role in 
determination of bone mineral density.23 ' 24 Candidate genes under study include 
vitamin D receptor (VDR) genes, 40' 45 the estrogen receptor gene,4649 the collagen 
type 1 alpha 1 (COLlA!) gene, 5°· 5 1 and genes that regulate the growth 
hormone/insulin-like growth factor-I (IGF-I) axis. 52• 53 Their role in bone mass 
development is under investigation, but this has not been adequately characterized 
to date. 
RACE AND ETHNICITY 
Due to racial and ethnic differences in BMD values, population norms have been 
established for use as DXA reference standards. 54-56 As a group, African 
American women achieve a higher peak bone mass than whites, show a slower 
subsequent rate of bone loss, and have a lower incidence of postmenopausal hip 
fracture. 57• 58 Asian Americans tend to have lower BMD values than whites, but 
they also have a lower rate of hip fracture. 59 
HORMONAL FACTORS 
Endogenous hormones 
Bone loss can occur in the setting of prolonged amenorrhea and estrogen 
deficiency. Davies et. al. measured lumbar spinal bone mass in 200 white women 
aged 16-40 seen in a reproductive medicine clinic for amenorrhea of a median 
duration of three years (range six months to 24 years). 60 Lumbar spinal BMD was 
15% lower in the amenorrheic women than in 57 age matched normal volunteers 
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(95% CI, 12-18%; absolute BMD values, 0.89 g/cm2 vs. 1.05 g/cm2). Patients 
who reported a history of fracture had 6.6% lower mean BMD than those who had 
never fractured (n=57, p=0.003). A prospective study of 54 professional dancers 
and 57 nondancers found lower lumbar spinal BMD at baseline and over the 
subsequent two years in both exercising and nonexercising amenorrheic women.61 
An increased incidence of stress fractures was associated with delayed menarche 
and lower spinal BMD. 
A small study of elite athletes indicated that premature bone loss might occur in 
women with lesser degrees ofhypoestrogenism, as evidenced by prolonged 
menstrual irregularity. Micklesfield et a!. measured BMD in 25 premenopausal 
ultramarathon runners aged 29-39 years, four of whom had current 
oligomenorrhea, two with current amenorrhea, and four with a history of mixed 
oligo/amenorrhea.62 Mean lumbar spinal BMD in women with a history of 
oligomenorrhea alone was 12.4% lower than in controls (p<0.005), but did not 
differ from the mean value in women with a history of both oligomenorrhea and 
amenorrhea 
Exogenous hormones 
In some past studies, oral contraceptive (OC) use was found to be associated with 
bone mass increases in premenopausal women. 63• 64 Interpretation of these studies 
is difficult for several reasons. The indication for OC use is usually unspecified, 
and women taking OC for oligo- or amenorrhea would be more likely to have low 
bone mass at baseline than those taking OC for contraception only. OC use could 
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potentially have a different effect on bone mass in women with low vs. normal 
bone mass at baseline. Also, OC users have been found to have lower BMI and to 
be more likely to smoke than controls in some studies, making confounding more 
likely. 
Two prospective studies of early premenopausal women who take OC have failed 
to show consistent gains in bone mass in response to estrogen. Prior et a!. 
examined oral contraceptive use in 524 women ages 25-45 participating in a 
multicenter, population-based cohort study, 454 of whom had taken oral 
contraceptives.65 Mean BMD values adjusted for age, BMI and height were 0.02-
0.04 gm/cm2 (2.3%-3.7%) lower in OC ever-users as compared to controls; 
differences were statistically significant at the lumbar spine and femoral 
trochanter. Results were similar for current and past OC users. The investigators 
postulated that comorbid lifestyle factors (more smoking and alcohol 
consumption in OC users) or a confounding effect of OC prescribed for 
oligo/amenorrhea may have contributed to these findings. An earlier cohort study 
of200 healthy women ages 19-22 years showed that 76 participants who took an 
oral monophasic contraceptive ( ethinyl estradiol 20 J.lg ± desogestrel 0.150 mg) 
for five years experienced no mean change in spinal BMD, while 71 non-users 
showed a 7.8% increase in spinal BMD by the end of the study.66 Considering the 
young age range of the participants, the lack of change in BMD associated with 
OC use suggested that exogenous estrogen may have attenuated the potential peak 
bone mass in users, while non-users achieved normal gains. These findings need 
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to be further validated to clarify the impact of OC use on bone mass in 
eumenorrheic women. 
Past prospective studies have shown conflicting results regarding the effect of 
depot medroxyprogesterone acetate (DMP A) administration on bone mass. Most 
of these studies involved small patient populations followed for periods as short 
as six months67• 68 A recent 3-year, population-based cohort study of 457 women 
ages 18-39 (183 DMPA users and 274 non-users) showed an annual mean rate of 
BMD change of -0.87% at the spine for the DMP A group vs. +0.40% for 
controls.69 Annual BMD change at the hip was -1.12% for the test group vs.-
0.05% for controls. The differences at both sites were statistically significant, and 
appeared to be reversible after discontinuation ofDMPA use. DMPA may cause 
lower endogenous estrogen levels, an effect that may not be generalizable to other 
forms of progestin-only contraception.70• 71 Ongoing multicenter studies will 
examine the impact ofDMP A on bone loss and reversibility after discontinuation 
of use. 
In summary, delayed menarche and amenorrhea are associated with lower spinal 
bone mass in premenopausal women. Limited evidence indicates that prolonged 
oligomenorrhea can have a similar effect on lumbar spinal BMD. Two 
prospective studies of premenopausal women did not show BMD increases in 
response to OC use. A recent population-based prospective study indicates that 
long-term administration ofDMPA is associated with bone density loss, but that 
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the loss may be reversible. Further studies are needed to support these 
conclusions. 
NUTRITIONAL FACTORS 
Cross-sectional studies and a limited number of small prospective studies have 
examined the impact of nutrition on bone mass in premenopausal women. While 
dietary influences have been the focus of numerous studies of postmenopausal 
osteoporosis, they are often secondary measures in premenopausal studies. For 
example, the effect of calcium intake on bone mass might be studied when 
calcium supplementation is provided during an exercise intervention or dieting 
program. As for all studies based on dietary histories, these studies are limited by 
recall bias and extrapolation of short-term data on food consumption. 
Calcium 
Ramsdale et a!. examined the relationship between bone mineral density and 
calcium intake in 56 healthy premenopausal women, ages 21-47. Statistically 
significant correlations were found between calcium intake and BMD at three 
femoral sites (neck r=0.41, Ward's triangle r=0.40, trochanter r=0.47, p < 0.001) 
and at the spine (r=0.27, p < 0.05).72 A cross-sectional study by Teegarden eta!. 
showed a more complex relationship between bone mass and nutrient intake.73 
Dietary intake was assessed from food frequency interviews in 215 white women 
ages 18-31 recruited for an exercise intervention study. The statistical model 
indicated that adequate intakes of calcium, protein and phosphorus were all 
required for significant bone density changes to occur. 
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Prospective studies have shown different findings in cohorts of different ages. A 
cohort study of 156 healthy white college students, followed for up to 5 years 
found an increase of 5.9% in lumbar spinal BMD64 Spinal BMD showed a weak 
positive correlation with calcium intake which was not statistically significant; 
however, a modest but statistically significant correlation was seen with the 
calcium/protein ratio (r=O.ZO, p=O.OZ). Citron et a!. examined the effect of 
calcium intake on spinal and radial BMD in a 4-year prospective study of 41 older 
premenopausal women, aged 38-42 years at baseline.74 Spinal bone mass declined 
-0.86 +/- 0.15% per year (p < 0.001); the rate of decline was not attenuated by 
calcium intake. 
Thus, several cross-sectional and prospective studies have failed to show a 
statistically significant association between BMD and calcium intake alone. 
However, calcium intake analyzed in conjunction with other nutrients appears to 
be a better predictor of spinal BMD in some studies. 
Protein 
Cooper et a!. studied the relationship of six key nutrients to axial and appendicular 
BMD in a cross-sectional, population-based study of pre- and post-menopausal 
women based on a 7 -day dietary record. 75 In the analysis of 72 premenopausal 
women, statistically significant positive associations were found between protein 
intake and BMD in the proximal femur and distal radius; these associations 
remained statistically significant after BMD values were adjusted for age, weight 
16 
and physical activity. Adjusted BMD values were not associated with calcium 
and phosphorus intake. The four premenopausal women who had a history of 
fractures at the hip, distal forearm or spine had significantly lower intakes of 
protein and phosphorus, and borderline lower intakes of calcium relative to other 
premenopausal women. These results suggest that protein intake may be an 
important determinant of bone mass in premenopausal women. 
Dieting and Weight Cycling 
The effect of voluntary weight loss on bone mineral density has been studied in 
several settings. Two small prospective studies of obese, premenopausal patients 
on physician-supervised weight loss interventions including phases of very-low-
calorie dieting demonstrated small, but statistically significant decreases in bone 
mineral content at the distal radius76 and hip77 after eight to 36 months of follow-
up. A randomized clinical trial examined bone mass in 236 healthy 
premenopausal women ages 44-50 recruited from the community to participate in 
a lifestyle intervention program for weight loss (dietary behavior modification and 
exercise recommendations).78 After 18 months of participation, the intervention 
group (n=115) had lost 3.2 ± 4.7 kg vs. a weight gain of0.42 ± 3.6 kg in controls 
(n=l21). The annual rate ofhip BMD loss was significantly higher in the 
intervention group vs. the controls (0.81% ± 1.3% loss vs. 0.42% ± 1.1% loss, p < 
0.001), despite the fact that intake of both dietary calcium and calcium 
supplements increased in the intervention group but decreased in controls. In 
contrast, Shapses et a!. reported that lumbar spinal BMD increased by I. 7% from 
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baseline in premenopausal obese women on a moderate weight loss plan with 
I 000 mg/day calcium supplementation (n=14).79 No significant change in lumbar 
spinal BMD was seen in dieters who did not receive calcium supplementation 
(n= 14) or in controls who maintained their body weight (n= I 0). 
Subtler degrees of eating restraint may also affect bone mass. Van Loan et al. 
measured significantly lower bone mineral content in women who had high scores 
on a cognitive eating restraint (CER) questionnaire as compared to women who 
had low CER scores.80 This effect was only seen in women who weighed< 71 
kg. Menstrual and hormonal differences were not assessed in the participants. 
Participants with high CER scores reported higher numbers of lifetime weight 
loss cycles (episodes of weight loss over 5 pounds). A cross-sectional study of 
129 premenopausal women ages 29-46 showed lower lumbar spinal BMD (-0.062 
g/cm2 vs. controls, p = 0.01) in participants who reported a history of weight 
cycling (weight loss of at least 5 kg, followed by regain of at least 50% of the 
loss). 
Thus, small degrees of bone loss have been observed in obese patients on very-
low-calorie diets. Two cross-sectional studies suggested that a high level of 
eating restraint and a history of repeated weight loss followed by regain may be 
associated with slightly lower bone mass. 
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PHYSICAL ACTIVITY 
Attempts to analyze the effect of physical activity on bone mass have been 
hampered by methodological problems in exercise intervention studies. These 
studies show wide variation in interventions and outcome measures, small effect 
sizes, frequent high dropout rates and variable compliance with test or control 
regimens. Wallace and Cumming recently published a systematic review of 
randomized trials of the effect of exercise on bone mass in pre- and 
postmenopausal women published from 1966 to 1997.81 They included eight 
randomized trials of premenopausal women; pooled results of these studies 
showed 1.5% (95% CI; 0.6%-2.4%) less bone loss per year in the lumbar spine 
after impact exercise (n=143; 73 exercisers, 70 controls), and 1.2% (95% CI; 
0.7%-1.7%) less loss after non-impact exercise (n=203; 95 exercisers, 108 
controls). At the femoral neck, impact exercise was associated with 0.9% less 
bone loss (95% CI; -0.2%-2.0%), which approached statistical significance 
(n=143; 73 exercisers, 70 controls). There were insufficient data to analyze the 
effect of non-impact exercise on bone mass at the femoral neck. 
Two studies published since the above systematic review have shown statistically 
significant increases in BMD from baseline in premenopausal women with high 
levels of physical activity,82' 83 however, neither of these studies showed 
statistically significant differences in BMD in the physically active women as 
compared to controls. Two earlier randomized, controlled trials showed 
statistically significant increases in lumbar spinal BMD in women who 
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participated in exercise interventions as compared to controls; notably, all 
participants took a calcium supplement throughout both of these trials. 84• 85 
Relevant prospective studies of exercise are summarized in Table 2. 82-86 
DISEASE FACTORS 
Anorexia nervosa and associated eating disorders 
Low bone mass is highly prevalent among patients with chronic anorexia nervosa 
(AN), especially in those with the binge-eating/purging subtype.87 In a cohort 
analysis of 130 women with AN recruited from the community, Grinspoon et al. 
found that 92% of participants met WHO criteria for osteopenia (BMD reduced 
by at least 1.0 SD) and 38% met criteria for osteoporosis (BMD reduced by at 
least 2.5 SD) at one or more skeletal sites88 Weight was a significant 
independent predictor ofBMD at all skeletal sites; age at menarche and time since 
last menstrual period were significant predictors of spinal BMD. Undernutrition, 
hypoestrogenism, and possibly endogenous cortisol excess are mechanisms for 
accelerated bone loss in these patients. Bone loss has the potential to be most 
severe in chronic AN when onset of disease is before attainment of peak bone 
mass.89 
Other diseases 
A recent systematic review 90 classified the following disease states as high risk 
(relative risk 2: 2) for fracture related to bone mass loss in predominantly 
postmenopausal women: primary hyperparathyroidism, type I diabetes mellitus, 
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anorexia nervosa, gastrectomy, pernicious anemia, prior osteoporotic fracture. 
Moderate-risk diseases (RR of fracture between 1 and 2) included 
hyperthyroidism, diabetes mellitus (type II or not specified), and rheumatoid 
arthritis. 
Accelerated bone loss may be associated with endocrine diseases that lead to 
hypoestrogenism (e.g., hyperprolactinemia,91 Sheehan's syndrome). Diseases for 
which glucocorticoid therapy is commonly prescribed (e.g., collagen vascular 
diseases,92 cystic fibrosis93) and conditions causing high endogenous levels of 
glucocorticoids (e.g., Cushing's Syndrome) may be associated with premature 
bone loss. Malabsorption syndromes, inflanunatory bowel disease and lactose 
intolerance94 can affect bone health in part by altering calcium and vitamin D 
absorption and intake. A recent population-based study of 322 women with a 
history of major depression compared to 644 controls showed that a lifetime 
history of major depression may be associated with earlier transition to 
perimenopause and its associated hypoestrogenic state, which could potentially 
lead to premature bone loss. 95 An Nlli -sponsored clinical trial is currently 
examining whether premenopausal women ages 21 to 45 with major depression 
lose bone mass at a faster rate than women without depression, and whether 
alendronate can preserve bone mass in premenopausal women with major 
d . d . % epresswn an osteoporosis. 
MEDICATIONS 
Glucocorticoids 
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A meta-analysis of 56 cross-sectional studies and ten longitudinal studies (total 
2891 corticosteroid users, 71.5% female, average age 55.2 years, age range and 
menopausal status not specified) concluded that oral doses greater than 5 mg per 
day of prednisolone or an equivalent lead to a reduction in bone mineral density 
and a rapid increase in fracture risk as early as 3 to 6 months after initiation of 
therapy.97 As discussed in this analysis, the increased fracture risk appears to be 
primarily due to a decline in bone density, but is probably also due to a 
deterioration in bone quality. The decline in quality is evidenced by higher 
fracture rates than expected based on bone density changes alone in patients with 
corticosteroid-induced osteoporosis. Prolonged use of inhaled steroids may also 
contribute to bone loss. 98• 99 Long-term steroid use can cause a decline in muscle 
mass, which could potentially increase fall risk. Although the American College 
of Rheumatology has published guidelines for BMD monitoring and preventive 
management in patients on long-term steroid therapy, 100 many patients taking 
chronic exogenous steroids fail to receive preventive therapy for bone loss. 101 
Other medications 
Although long-term thyroid supplementation has been associated with significant 
osteopenia in cross-sectional studies, 102 a recent systematic review of cohort 
studies and case controls studies90 and a large cohort study of postmenopausal 
white women34 did not indicate an independent association with fracture risk. In 
the latter study, current use of anticonvulsant drugs was associated with increased 
hip fracture risk in an age-adjusted model (RR 2.8; 95% CI, 1.2-6.3), even though 
a previous analysis did not show an association between use of anticonvulsant 
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drugs and lower appendicular bone mass. 103 A meta-analysis of nine cross-
sectional studies oflong-term oral anticoagulant exposure found a modest 
negative association with bone density in the ultradistal radius, but no significant 
association with bone density in the distal radius, spine or hip. 104 
SMOKING 
Two meta-analyses since 1997 have reported statistically significant lower BMD 
h h. . I k d k 1os 106 S kin at t e 1p m ong-term smo ers as compare to nonsmo ers. ' mo g may 
exert its effect on bone by altering calcium and vitamin D metabolism.107• 108 
Clinical outcomes 
Osteoporosis itself is clinically silent; the disorder has clinical and public health 
importance only because it increases the risk of disabling osteoporotic 
fractures. 109 These outcomes are well studied in postmenopausal women. 
Although certain high-risk young adults may have BMD in the osteoporotic 
range, these patients have a low fall risk, and greater muscle strength and 
dexterity to protect themselves from higher impact falls. How often, and how 
early, do complications occur in premenopausal patients? Both immediate and 
long-term clinical outcomes should be considered. 
IMMEDIATE CLINICAL OUTCOMES 
Premenopausal osteoporotic fractures are rare; however, early fragility fractures 
have been documented. In a descriptive study of 52 consecutive premenopausal 
women ages 20-51 referred to an outpatient rheumatology clinic primarily for 
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osteoporosis management, Peris et a!. found 15 patients (29%) with vertebral 
fractures and 12 with previous peripheral fractures. 38 
Low bone mass has been associated with an increased incidence of stress fractures 
. " I hi 110 d .,. . 111 C . . I h m 1ema e at etes an m1 1tary recrmts. ertam occupatwna groups, sue 
as ballerinas are at increased risk of delayed menarche and hypothalamic 
amenorrhea leading to osteopenia and stress fractures. 112 A survey of 7 5 dancers 
found 61% (n=46) reported a history of fracture, and 69% of the fractures 
described were stress fractures. 113 Early stress fractures 114 and vertebral 
fractures115 were documented in case series of patients with anorexia nervosa 
(AN). A population-based retrospective cohort study assessed long-term fracture 
risk in 208 patients with AN followed for a total of2689 person-years.116 Forty-
five patients sustained 88 fractures; the cumulative incidence of any fracture at 40 
years after the diagnosis of anorexia nervosa was 57%. Fractures of the hip, spine 
and forearm occurred long after disease onset (on average 24 to 38 years after 
diagnosis). 
Adolescent idiopathic scoliosis has been associated with persistent osteopenia in a 
small cohort study, 117 and with low BMI due to presumed disordered eating in a 
cross-sectional study of 44 young women. 118 A 24% prevalence of scoliosis was 
reported in an early study of young ballet dancers113; this value is substantially 
higher than the 2% prevalence of scoliosis reported in school-age children and 
adolescents. 119' 120 
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LATE CLINICAL OUTCOMES 
Retrospective data from postmenopausal studies suggest that fractures in early 
adulthood may predict fractures in the peri- and postmenopausal period (Table 
3).3• 121 -124 A recent report from the Study of Osteoporotic Fractures (SOP) cohort 
of 9086 white women aged 65 and older indicated that premenopausal fracture is 
an independent risk factor for postmenopausal fracture. 121 For women with a 
history of premenopausal fracture, the hazard ratio of fractures of all types during 
12 years offollow-up was 1.25 (95% CI; 1.03, 1.50) after adjustment for age, 
BMD, BMI, use of steroid and anticonvulsant medications, number of falls, and 
maternal fracture history. This effect persisted after stratification by estrogen use, 
propensity to fracture, and maternal fracture history. Similarly, a large 
retrospective, population-based study by Honkanen et a!. found that a history of 
any fracture at ages 20-34 was associated with an increased risk of fracture at ages 
35-57 (HR 1.9; 95% CI 1.6, 2.3)_3 
In summary, descriptive studies have shown low bone mass and a higher 
incidence of stress fractures in premenopausal women with certain disease states 
associated with prolonged amenorrhea, nutritional deprivation and/or excessive 
exercise. Premenopausal fragility fractures are rare; however, premenopausal 
fractures of any type are an independent predictor of postmenopausal fractures. 
Management 
TREATMENT ISSUES 
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Early treatment interventions have been studied in premenopausal patients with 
secondary osteoporosis from a variety of causes. A Cochrane Review assessed 
the efficacy ofbisphosphonates for prevention and treatment of corticosteroid-
induced osteoporosis. 125 This systematic review included 13 controlled clinical 
trials of 842 adults, most of whom were taking chronic corticosteroids for 
collagen vascular diseases (esp. rheumatoid arthritis, lupus), asthma or COPD. 
The weighted mean differences of bone mineral density between the treatment 
and placebo groups were 4.3% (95% CI, 2.7, 5.9) at the lumbar spine and 2.1% 
(95% CI, 0.01, 3.8) at the femoral neck. Efficacy regarding fracture prevention 
could not be determined. Currently, treatment trials are underway examining the 
efficacy ofbisphosphonates in preventing and/or treating bone loss in 
premenopausal women with premature ovarian failure due to chemotherapy for 
breast cancer, in cystic fibrosis patients, and in children with idiopathic juvenile 
osteoporosis.96 
A randomized, controlled trial by Klibanski et a!. (n=48) 126 and a recent 
prospective cohort study (n=50)127 showed that estrogen-progestin replacement 
therapy did not prevent progressive bone loss in premenopausal patients with 
anorexia nervosa. Raloxifene was found to prevent GnRH-agonist-related bone 
loss in a single-blind, randomized controlled trial of I 00 premenopausal women 
receiving treatment for uterine leiomyomas.128 
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Safety of bone-protective agents for women of reproductive age must be 
considered. For example, bisphosphonates have a Category C rating for safety in 
pregnancy, based on toxic effects at parturition in the rat model. 129 
Bisphosphonates have been shown to pass through the rat placenta and 
accumulate in fetuses. 130 These agents may be stored in bone for long periods, 
and the long-term implications for women of childbearing age are uncertain. 
Potential risks and lack of efficacy data on fracture risk reduction in 
premenopausal women must be weighed against the proven efficacy of 
bisphosphonates to decrease fractures in postmenopausal women. 131 • 132 
Bisphosphonate use should be limited in premenopausal women and reserved for 
those individuals with fragility fractures or clearly accelerated bone loss rather 
than low peak bone mass alone. 
SCREENING ISSUES 
Although some clinical outcomes may occur early, screening for premenopausal 
osteoporosis in the general population is not feasible. The US Preventive 
Services Task Force considers screening in women younger than age 60 a Grade 
C recommendation, i.e., although the Task Force found at least fair evidence that 
this process can improve health outcomes (prevent fractures), it concluded that the 
balance of benefits and harms is too close to justif'y a general recommendation.133 
The National Osteoporosis Foundation mentions that current data are insufficient 
to formulate specific recommendations for premenopausal women, nonwhite 
women or men. However, the NOF recommends that risk factors be used on an 
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individual basis to determine the need for bone density testing and treatment, and 
that all people should follow universal recommendations for bone health. 134 
A case-finding strategy could be considered for premenopausal women with 
disease conditions known to be strongly associated with accelerated bone loss. 
Early detection of osteoporosis could allow interventions at an age when 
appropriate measures could maximize bone accrual and minimize loss over a 
much longer time period before menopause. Some interventions are more likely 
to be effective in younger women; for example, more strenuous physical activity 
can be recommended to younger patients, and they may be more likely to comply 
with exercise prescriptions than peri- and postmenopausal women. Moreover, 
older patients are more likely to have already sustained fractures or to have 
comorbid conditions that could limit their ability to comply with an exercise 
regtmen. 
However, advantages of early detection must be weighed against potential harms, 
which include treatment-associated morbidity, inappropriate treatment of patients 
with false positive tests, prolonged psychological distress in some patients over 
misperceived fracture risk, and misallocation of resources if more lives could be 
saved or improved through other preventive measures. Existing evidence 
regarding the balance of benefits and harms is insufficient to allow reasonable 
cost-effective analyses of screening strategies for premenopausal osteoporosis. 
GUIDELINES 
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A search of the National Guidelines Clearinghouse in November 2002 revealed 
eight practice guidelines directly relating to osteoporosis management. Four of 
these guidelines offer some diagnostic or treatment information for 
premenopausal patients6• 100• 135• 136; the fifth mentions that its prevention 
guidelines apply to adults of all ages. 137 Notably, the 2001 update of the 
American College of Rheumatology Recommendations for the Prevention and 
Treatment of Glucocorticoid-induced Osteoporosis specifies that prevention of 
bone loss with antiresorptive agents should be considered for premenopausal 
women receiving glucocorticoid therapy.100 
Conclusion 
Evidence to date does not support screening for osteoporosis in premenopausal 
women in the general population. However, certain patient populations are at 
higher risk of accelerated bone loss at an early age; a systematic method for 
identifying these patients in primary care is lacking. Further research must clarify 
the relative importance of risk factors for early bone loss and better document the 
potential benefits and harms of screening before a useful approach to selective 
screening can be developed. Until then, we will rely on heightened knowledge of 
primary care physicians to identify young women who may need early bone 
health assessment and preventive interventions. The evidence reviewed in this 
article supports consideration of risk assessment and bone density testing for 
premenopausal women with the following conditions: frequent or prolonged use 
of corticosteroid medications (?: 5mg oral prednisolone or equivalent per day for 
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at least three months), past or current anorexia nervosa, prolonged or recurrent 
amenorrhea, hyperparathyroidism, rheumatoid arthritis, hyperthyroidism. Patients 
with abnormally low bone density will often require additional laboratory work-
up, nutritional evaluation, or specialty referral. 
Future research should focus on prevention in addition to therapeutic 
interventions. Health care providers also need to increase patient education on 
modifiable disease factors, including optimal nutrition from birth, age-appropriate 
regular weight-bearing exercise, smoking cessation, and minimization of 
environmental risk factors for fracture. The goal should be to institute age-
appropriate interventions at a stage when bone quality is intact and futnre loss can 
be minimized. 
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Table 1: Prospective studies of bone mineral density in premenopausal women 
Change in femoral neck BMD Change in lumbar spinal BMD 
Study Length of Participants g/cm' per % change from g/cm' per % change from 
follow-up year baseline per year year baseline per year 
Bainbridge et 6 years 614 women ages 24-44 -0.003* -0.3%* Varied with time 
a!. 200229 
Hui eta!. 1-9 years 130 premenopausal white women, ages 31-50 -0.00357 -0.43%* -0.00209 -0.19% 
200230 (mean3.9) ± 0.0025* ± 0.0050 
Salamone et a!. 30 months 290 premenopausal white No menopausal - - -0.0018 -0.17% ±_ 1.1% 
199831 women, ages 44-50 symptoms 
At least one - - -0.0050* -0.50 ± 1.3%* 
menopausal symptom 
Slemenda et al. 2-8 years 96 premenopausal women, ages 30-48 -0.0021 -0.25%* +0.0036 +0.32% 
199632 ± 0.013* ±_0.012 
BMD, bone mineral density 
* p < 0.05 for comparison of follow-up value to baseline value 
------1"-'1"1"'' 
Table 2. Physical activity and bone mineral density in premenopausal women 
Change in femoral neck 
BMD+ 
Change in lumbar spinal 
BMD+ 
Study Type Exercise g/cm' %change g/cm' Participants per from baseline per 
year per year year 
Ito eta!. 24-month observational Volleyball 26 premenopausal Asian Exercise group - - 0.001 
2001 86 study women ages 42-49 (n=l3) 
Sedentary - - -0.011 
controls (n=l3) 
Goto eta!. 12-month prospective Walking 12 premenopausal Exercise group 0.022 2.67%* 0.009 
2001 82 cohort study Asian women ages 35-42 (n=6) ± 0.015* ± 0.015 
Sedentary -0.006 ± -0.78% 0.011 
controls (n=6) 0.014 ± 0.027 
Winters et a!. 18-month Jumping and 49 premenopausal women Exercise group 0.008* 1.2% 0.010 
200083 nonrandomized resistance ages 30-45 (n=29) ±3.2%* 
controlled trial exercises 
Sedentary -0.002 -0.03 ± 1.9% 0.002 
controls (n=20) 
DornemaiUl et 6-month unblinded Resistance 3 5 premenopausal women Exercise group 0.020* 2.62%* 0.0201 
a!. 1997 '" randomized controlled exercises ages 40-50. All participants (n= 12,6 
trial took a 500 mg/day calcium dropouts) 
supplement throughout the Sedentary 0.022* 2.44%* -0.008 
study. controls (n = 14, 
3 dropouts) 
Lohman et a!. 18-month unblinded Weight-lifting I 06 white premenopausal Exercise group -0.003 -0.32% 0.019' 
199585 randomized controlled women ages 28-39. All (n=22,37 
trial participants took a 500 dropouts) 
mg/day calcium supplement Sedentary -0.015 -1.57% -0.008 
throughout study. controls (n=34, 
13 dropouts) 
BMD, bone mineral density 
11 BMD values extrapolated from 6-month follow-up data 
* p < 0.05 for comparison of post-training value to pre-training value +values were calculated if not reported in study 
t p < 0.05 for comparison of exercise group to control group 
%change 
from baseline 
per year 
0.05% 
-0.94% 
0.90% 
1.06% 
1.1% ±3.0% 
0.2% ± 1.9% 
2.00% 
-0.72% 
1.61%' 
-0.65% 
I 
' 

Table 3. Relationship between premenopausal and postmenopausal fracture 
Study Type 
Hosmer et al. 2002 "' 12-year prospective 
population-based 
cohort study 
Wu eta!. 2002 '" Cross-sectional 
Goulding et a!. 1997 ><> Cross-sectional 
Honkanen et al. 1997' Retrospective 
population-based 
study 
Torgerson et al. 1996 '"' 2-year prospective 
population-based 
cohort study 
DXA, dual x-ray absorptiometry 
BMD, bone mineral density 
BMC, bone mineral content 
LS, lumbar spme 
OR, odds ratio 
Participants Outcome 
measures 
9086 ambulatory white women age 65 Fractnres that 
years and older. occurred after study 
enrollment. 
1284 women, at least 10 years post- Retrospective self-
menopausal, mean age ± SD: 73 ± 4 report of fracture 
years. 
59 eumenorrheic premenopausal DXA-BMDand 
women, ages 40-55 BMCofLS 
12,162 women ages 47-56 years in total Retrospective self-
study population.; 2412 women in report of fractnre 
BMD substudy with mean± SD age 
53.24 ± 2.80 years DXA-BMD ofLS 
and femoral neck 
1857 perimenopausal women ages 47- Fractnres that 
51 occurred after study 
enrollment 
''"""--i-><!•ijlfl""'"''"'" ···><-1"'1"1'''''"' 
Findings 
Women with a history of premenopausal fracture were 
more likely to sustain a fractnre during the study period 
than women without a history of fractnre. Adjusted 
hazard ratio: 1.25; 95% CI, 1.03-1.50. 
Women with a history of fractnres between the ages of 
20 and 50 years had 1.74 times the odds of sustaining a 
fractnre after age 50 (OR, 1.74; 95% CI, 1.12-2.70). 
Fractures occurring before age 20 were not associated 
with increased odds of fracture after age 50 (OR, 1.01; 
CI 0.66-1.56) 
Women with a history of fractnres had significantly 
lower BMD (6% less) than women who had never 
fractured. 
Women with a history of fractnres between the ages of 
20 and 34 were more likely to sustain a fracture 
between the ages of35 and 57 than women without this 
history. (Hazard ratio 1.9; 95% CI, 1.6-2.3) 
An early premenopausal, low-energy wrist fracture was 
associated with 10.5% lower femoral BMD than for 
nonfractnred women (p~O .026). 
Women with a history of fractnre, had 2 times the odds 
of sustaining a fractnre during the study period (95% 
CI, 1.31-3.03). 
After adjusting for covariates, the OR of sustaining a 
fractnre was 1.6 (95% CI, 1.16-2.34) for each SD 
reduction in BMD at the spine 
Family history of hip fractnre (maternal grandmother) 
carried OR 3.7 (95% CI, 1.55-8.85). Postmenopausal 
or history of hysterectomy carried OR 1.98 (1.02-3.56). 
Clinical Considerations in Premenopausal 
Osteoporosis 
Margaret L Gourlay, MD; Sue A. Brown, MD 
0 steoporosis can occur at any age. In premenopausal osteoporosis, full achievement of peak bone mass may be curtailed, and accelerated bone loss may occur in young adulthood. Premenopausal osteoporosis may be associated with chronic glucocor-ticoid therapy, prolonged amenorrhea, anorexia nervosa, rheumatoid arthritis, and 
diseases that affect calcium and vitamin D metabolism. Lesser degrees of bone loss may be asso-
ciated with common conditions such as dieting, low calcium intake, smoking, and oligomenor-
rhea. Owing to a paucity of prospective studies on screening and treatment in younger age groups, 
few practice recommendations exist to guide the management of osteoporosis in young adults. 
We review the most important clinical concerns in premenopausal osteoporosis, including mea-
surement of bone mass, normal bone accrual, risk factors for premature bone loss, clinical out-
comes, and management issues. We emphasize clinically relevant information for primary care 
physicians, who are usually the first to encounter premenopausal patients with risk factors for 
early bone loss. Arch Intern Med. 2004;164:603-614 
Although low bone mass and accelerated 
bone loss can occur early in life, osteopo-
rosis is usually considered a disorder of 
postmenopausal women. The most seri-
ous consequences of osteoporosis occur in 
this age group, and treatment outcomes 
may be poor after a fracture late in life. Hip 
fractures cause the most morbidity and 
mortality; the hip fracture incidence in 
white women increases 10-fold from 50.1 
per l 00 000 per year between ages 50 and 
54 years to 530.5 per 100000 per year be-
tween ages 70 and 74years. 1 Vertebral frac-
tures and distal forearm (Calles) frac-
tures occur more commonly after 
menopause and are associated with a 
higher subsequent rate of hip fracture.M 
Certain groups of premenopausal 
women are at high Iisk of osteoporosis, in-
cluding those with disease states or exog-
enous influences that promote acceler-
ated bone loss. The 2001 National 
Institutes of Health Consensus Develop-
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ment Panel on Osteoporosis Prevention, 
Diagnosis, and Therapy5 specified peak 
bone mass in children and secondary os-
teoporosis in young adults as important 
areas for future research. Relatively little 
is known about early-onset osteoporosis, 
and, to our knowledge, no general prac-
tice recommendations exist to guide di-
agnosis and therapy. 
We present an overview of the most 
important clinical concerns in premeno-
pausal osteoporosis, with the goal of in-
creasing awareness of high-risk patients, 
who often are first seen by primary care 
physicians. This review addresses mea-
surement of bone mass, normal bone ac-
crual, risk factors for premature bone loss, 
clinical outcomes, and management is-
sues in premenopausal women. 
METHODS 
We searched the MEDLlNE/PubMed data-
base Qanuary 1984 to August 2002) using the 
follov.ing MeSH tenns and keyvlOrds: "osteo-
porosis" AND "premenopause" for articles on 
premenopausal osteoporosis and "bone dis~ 
eases, metabolic" OR "low bone mass" OR 
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"bone density" OR "osteopenia," AND 
'·premenopau .. se" NOT "osteoporosis" for 
articles on premenopausal osteopenia. 
We revie\ved abstracts for all English~ 
language citations in peer-reviewedjour-
nals and excluded the following: stud-
ies that only included perimenopausal 
or postmenopausal women; studies with 
premenopausal women as a reference 
group/control only, without analysis and 
discussion of relevant outcomes in pre-
menopausal patients; studies Vl'ith a lack 
of osteoporosis-related health out-
comes; studies with the purpose of veri-
fying an experimental radiologic diag-
nostic tool; and studies of insufficient 
length to assess significant change in out-
come. 
Our initial search yielded 287 ar-
ticles on premenopausal osteoporosis, 
176 ofwhich were excluded, and 202 ar-
ticles on osteopenia, 126 of which were 
excluded; the remaining 187 articles 
were reviewed for relevance and qual-
ity. An additional 185 articles from 
supplementary searches and hand 
searches of reference lists were evalu-
ated. Owing to the broad scope of this 
review and the general paucity of pro-
spective studies from our searches, we 
considered all study designs except case 
reports and diagnostic test verification 
studies. One of us (M.L.G.) used a check-
list to evaluate the internal validity of sci-
entific studies, systematic reviews, and 
meta-analyses. 
BONE DENSITY 
IN YOUNGER PATIENTS 
The National Institutes of Health 
Consensus Panel 2000 adopted a 
definition of osteoporosis as a skel-
etal disorder characterized by com-
promised bone strength predispos-
ing to an increased risk of fracture. 6 
Bone strength is determined by bone 
density and bone quality. 
Because fragility fractures are 
rare in young patients, they are usu-
ally not used as outcomes in stud-
ies of premenopausal bone loss, and 
they do not serve as the basis for the 
diagnosis of early-onset osteoporo-
sis. Instead, bone densitometry mea-
surements are used as surrogate in-
dicators of fracture risk. The 
relationship between bone mineral 
density (BMD) measures and frac-
ture risk is unclear in premeno-
pausal women. In postmenopausal 
women, a strong relationship ex-
ists between BMD and fracture risk, 
such that a 10% decrease in BMD 
confers a 1.6- to 2.6-fold increased 
rtsk for spine and hip fracture. 7 
BMD Measurement 
in Younger Patients 
Bone mineral density is a 2-dimen-
sional, areal projection mea.c;urement 
defined as the average concentration 
of mineral per unit area, expressed in 
grams per square centimeter.8 It is 
usually measured using dual-energy 
x-ray absorptiometry (DXA) or, in 
some cases, single-energy x-ray ab-
sorptiometry. 
Bone mineral density is re-
ported using 2 scores based on SD 
measurements: the Z score and the 
T score. The Z score compares the pa-
tient's BMD with the mean value in 
age-matched normal individuals. This 
is the most appropriate measure to 
use for children and young adults, 
who have yet to achieve their life-
time peak bone mass. The T score 
compares the patient's BMD to the 
mean value in a healthy young ref-
erence population, assumed to rep-
resent a standard for peak bone mass. 
Both scores may be adjusted for race 
and sex. A T score of -2.5 or lower 
meets World Health Organization cri-
teria for osteoporosis.9 AT score be-
tween -2.5 and -1.0 represents os-
teopenia; however, because fracture 
risk may vary widely based on age 
and other factors for patients with os-
teopenia, this categorization is oflim~ 
ited clinical value. 8 
Several factors should be con-
sidered when assessing bone den-
sity during periods of longitudinal 
growth. First, bone density measure-
ments obtained using DXA reflect a 
2-dlmensional rather than a 3-di-
mensional projection and may in-
accurately capture geometric 
changes or increases in bone size that 
occur during growth. In addition, the 
2-dimensional DXA measure may 
suggest a falsely lower BMD in small-
framed individuals, which could be 
particularly important in evaluat-
ing premenopausal women. Other 
techniques, such as quantitative 
computed tomography, measure 
bone volume (in grams per cubic 
centimeter) and may better charac-
terize changes in total bone mass that 
occur during growth; however, their 
use is limited owing to cost and ra-
diation exposure. Second, bone den-
sity and calcium accrual vary by site 
of measurement, with a general trend 
toward earlier bone density accrual 
in the proximal femur and verte-
bral body and later accrual at other 
sites. 1° Finally, small changes in 
BMD may be due to the random vari-
ability in the DXA test; changes of 
less than approximately 5.6% can of-
ten be due to precision error and 
should be interpreted cautiously.8 
Bone mineral density is most of-
ten measured at the lumbar spine and 
proximal femur because measure..s at 
these sites have been best validated 
against fracture in postmenopausal 
women. Discordance in BMD scores 
at these sites is common in young 
women, probably because of differ-
ing rates of bone accrual and loss. 
Bannick et al11 studied BMD values 
in 237 premenopausal vvomen and 
reported that a difference in Z score 
of more than 1 occutTedbetween the 
spine and the proximal femur in 20% 
to 24% of women aged 20 to 29years 
and in 32% to 46% of women aged 
30 to 45 years. Peripheral DXA mea-
surements of the distal radius and cal-
caneus can be performed; however, 
these values may not correlate with 
spine and hip measures and do not 
predict hip fractures as well as hip 
BMD." Until peripheral DXA has 
been further validated against frac-
ture, abnormal peripheral measures 
should be followed up with addi-
tional measurements of the spine and 
hip to confirm a diagnosis of osteo-
porosis. 
Attainment of Peak Bone Mass 
Peak rates of calcium accrual occur 
before age 30 years. Longitudinal 
studies have demonstrated that cal-
cium utilization increases during 
early puberty13 and that the highest 
rates of calcium accrual may occur 
at a mean age of 121/2 years in girls 
and 14 years in boysY' After this 
period of rapid calcium accretion, a 
period of bone consolidation is 
thought to ensue between ages 20 
and 30 years. Calcium accrual rates 
change little during this period, 
but periosteal expansion (outer 
surface of bone) may be increas-
ing.10 These periosteal changes 
could theoretically confer greater 
stnlctural integrity and would not 
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Abbreviations: BMD, bone mineral density; NA, not assessed. 
*Some values are given as mean only because the SD was not reported and could not be calculated. 
tP<.05 for follow-up value vs baseline value. 
be adequateJy detected by bone 
density rneasuremenLs using DXA. 
One15 study found that the inde-
pendent determinants ofBMD dur~ 
ing growth are Tanner stage in 
girls and weight in boys. Owing to 
the complex processes that occur 
during bone development, changes 
in bone mass in growing individu-
als may be difficult to interpret. 
Several investigatorsHi· 17 have 
begun to develop normative data-
bases to more accurately define 
expected BMD values for younger 
age ranges. 
Factors affecting the attain-
ment of peak bone mass have re-
cently been reviewed. 18,19 The pre-
cise age at which peak bone mass 
occurs is unknown. Population-
based, cross-sectional studies20•21 in-
dicate that women may attain peak 
bone mass in their 20s at the proxi-
mal femur and near age 30 years at 
the spine and forearm; however, age 
of att:'1inment could vary in healthy 
individuals. 22 A cross-sectional study 
of 265 premenopausal white fe-
males aged 8 to 50 years showed that 
most of the bone mass at multiple 
skeletal sites is accumulated by late 
adolescence. 10 
Multiple factors affect attain-
ment of peak bone mass, including 
genetic background, nutritional in-
fluences, and activity leveL Twin23 
and family 24 studies suggest that 50% 
to 80% of the variance in bone mass 
is heritable. A strong association has 
been noted between bone densities 
in mother/daughter pairs, which may 
be apparent before the daughter has 
begun puberty. 25"27 
Bone Mass in Premenopause 
Sowers and Galuska28 published a 
comprehensive review of the epide-
miology of bone mass in premeno-
pausal women in 1993. They re-
ported conflicting findings regarding 
BMD status after the attainment of 
peak bone mass and before the onset 
of menopause. Most cross-sectional 
studies from the 1980s and early 
1990s reported stable BMD in the pre-
menopausal period. However, most 
prospective and cross-sectional stud-
ies29"32 since 1994 have reported a 
small degree of loss ( <0.5°kl per year) 
during this period, especially at the 
proximal femur and more often in 
women with subclinical or clinical 
ovulation disturbances or meno-
pausal symptoms (Table 1). 
RISK FACTORS FOR 
PREMENOPAUSAL 
OSTEOPOROSIS 
Risk factors for low bone mass and 
osteoporotic fractures have been well 
studied in perimenopausal and post-
menopausal patients.33-36 Few stud-
ies have comprehensively exam-
ined predictors in younger patients. 
Moreira-Kulak et aP7 studied lll 
premenopausal and perimeno-
pausal women younger than 55 years 
with T scores of -2.0 or less at 1 or 
more anatomic sites who were re-
ferred to a tertiary care center for 
metabolic bone disorders. Seventy-
three of these women (66%) had an 
identifiable cause of bone loss. Con-
ditions associated -with estrogen de-
ficiency and the use of glucocorti-
coid therapy were the most common 
known causes of osteoporosis. How-
ever, 38 women (34%), 21 of whom 
were premenopausal, had no iden-
tifiable cause oflow bone mass. Peris 
et al-'8 studied 52 premenopausal os-
teoporotic women aged 20 to 51 
years who were referred to an out-
patient rheumatology clinic for os-
teoporosis evaluation and similarly 
found that 29 (56%) had no identi-
fiable predisposing condition. 
Tudor-Locke and McColP9 re-
cently revie\ved risk factors for varia-
tion in bone status in premeno-
pausal women aged 20 to 50 years. 
Nonmodifiable risk factors include 
genetic effects and race and ethnic-
ity. Potentially modifiable catego-
ries of risk include hormonal and nu-
tritional factors, physical activity, 
medications, and smoking. Certain 
disease states known to be associ-
ated with early bone loss can be sec-
ondary causes of osteoporosis. 
Genetic Influences 
Twin23 and family 24 studies have 
shown that genetic factors play an im-
portant role in determining BMD. 
Candidate genes under study in-
clude vitamin D receptor (VDR) 
genes,40-45 the estrogen receptor 
gene,46-49 the collagen type l alpha 1 
(COLlA]) gene, 50·51 and genes that 
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regulate the grmvth hormone/insulin-
like grmvth factor I a.xis.52.53 Their role 
in bone mass development is under 
inve..stigation, but this ha<> not been ad-
equately characterized to date. 
Race and Ethnidty 
Owing to racial and ethnic differ-
ences in BMD values, population 
norms have been established for use 
as DXA reference standards. 5-I-56 As 
a group, African American women 
achieve a higher peak bone mass 
than whites, show a slower subse-
quent rate of bone loss, and have a 
lower incidence of postmeno-
pausal hip fracture. 57·:m Asian Ameri-
cans tend to have lower BMD val-
ues than whites, but they also have 
a lower rate of hip fracture. 59 
Hormonal Factors 
Endogenous Hormones. Bone loss 
can occur in the setting of pro-
longed amenonhea and estrogen de-
ficiency. Davies etal60 measured lum-
bar spinal bone mass in 200 white 
women aged 16 to 40 years seen in a 
reproductive medicine clinic for 
amenorrhea of a median duration o[ 
3years (range, 6months to 24years). 
Lumbar spinal BMD was 15% lower 
in the women with amenorrhea than 
in 57 age-matched controls (95% con-
fidence interval [ Cl], 12%-18%; ab-
solute BMDvalues, 0.89 glcm2 vs 1.05 
glcm2). Patients who reported a his-
tory of fracture had 6.6% lower mean 
BMD than those who never had a frac-
ture (n=57; P= .003). A prospective 
study61 of 54 professional dancers and 
57 nondance.rs found lower lumbar 
spinal BMD values at baseline and 
during the subsequent 2 years in ex-
ercising and nonexercising women 
with amenorrhea. An increased inci-
dence of stress fractures was associ-
ated vvith delayed menarche and 
lower spinal BMD. 
A small study of elite athletes in-
dica ted that premature bone loss 
might occur in women with lesser de-
grees of hypoestrogenism, as evi-
denced by prolonged menstrual ir-
regularity. Micldesfield et al62 
measured BMD in 25 premeno-
pausal ultramarathon nmners aged 29 
to 39 years ( 4 had current oligomen-
orrhea, 2 had current amenorrhea, 
and 4 had a history of mixed 
oligomenorrhea/amenorrhea). Mean 
lumbar spinal BMD in women with 
a history of oligomenorrhea alone 
was 12.4% lower than in controls 
(P<.005) but did not differ from the 
mean value in women with a history 
of oligomenorrhea and amenorrhea. 
Exogenous Hormones. In somestud-
ies,61·M oral contraceptive (OC) use 
has been associated with bone mass 
increases in premenopausal women. 
Interpretation of these studies is dif-
ficult for several reasons. The indi-
cation for OC use is usually unspeci-
fied, and women taking OCs for 
oligomenorrhea or amenorrhea 
would be more likely to have low 
bone mass at baseline than would 
those taking OCs for contraception 
only. Use of OCs could potentially 
have a different effect on bone mass 
in women with low vs nonnal bone 
mass at baseline. Also, OC users have 
been found to have a lower body mass 
index and to be more likely to smoke 
than controls in some studies, mak-
ing confounding more likely. 
Two prospective studies of early 
premenopausal women who take OCs 
have failed to show consistent gains 
in bone mass in response to estro-
gen therapy. Prior et al65 examined 
OC use in 524 women aged 25 to 45 
years participating in a multicenter, 
population-based cohort study, 454 
of whom had taken OCs. Mean BMD 
values adjusted for age, body mass in-
dex, and height were 0.02 to 0.04 
glcm2 (2.3%-3. 7°;()) lower in women 
who had ever used OCs compared 
with controls; differences were sta-
tistically significant at the lumbar 
spine and femoral trochanter. Re-
sults were similar for current and past 
OC users. The investigators postu-
lated that comorbicllifestyle factors 
(more smoking and alcohol con-
sumption in OC users) or a confound-
ing effect of OCs prescribed for oli-
gomenorrhea/amenorrhea may have 
contributed to the..<>e findings. An ear-
lier cohort study66 of 200 healthy 
women aged 19 to 22 years showed 
that 76 participants who took an oral 
monophasic contraceptive (ethinyl es-
tradiol [20 j.lg] ±desogestrel [0.150 
mg]) for 5 years experienced no mean 
change in spinal BMD, whereas 71 
nonusers showed a 7.8% increase in 
spinal BMD by the end of the study. 
Considering the young age range of 
the participants, the lack of change in 
BMD associated with OC use sug-
gested that exogenous estrogen may 
have attenuated the potential peak 
bone mass in users, whereas nonus-
ers achieved normal gains. These find-
ings need to be further validated to 
clarify the impact of OC use on bone 
mass in eumenorrheic women. 
Past prospective. studies have 
shown conflicting results regarding 
the effect of depot medroxyproges-
terone acetate administration on bone 
mass. Most of these studies67•68 in-
volved small patient populations fol-
lowed for as little as 6 months. Are-
cent 3-year population-based cohort 
study69 of 457 women aged 18 to 39 
years (183 depot medroxyprogester-
one acetate users and 274 nonusers) 
showed an annual mean rate ofBMD 
change of-0.87% at the spine for the 
treatment group vs +0.40% for con-
trols. Annual BMD change at the hip 
was -1.12% for the test group vs 
-0.05% for controls. The differences 
at both sites were statistically signifi-
cant and seemed to be reversible af-
ter discontinuation of depot medroxy-
progesterone acetate use. Use of depot 
medroxyprogesterone acetate may 
cause lower endogenous e..strogen lev-
els, an effect that may not be gener-
alizable to other forms of progestin-
only contraception.70·71 Ongoing 
multicenter studies will examine the 
impact of depot medroxyprogester-
one acetate on bone loss and revers-
ibility after discontinuation of use. 
In summary, delayed menar-
che and amenorrhea are associated 
with lower spinal bone mass in pre-
menopausal women. Limited evi-
dence indicates that prolonged oli-
gomenorrhea can have a similar effect 
on lumbar spinal BMD. Two prospec-
tive studies of premenopausal women 
did not show BMD increases in re-
sponse to OC use. A recent popula-
tion-based prospective study indi-
cated that long-term administration 
of depot medroxyprogesterone ac-
etate is associated with bone density 
loss but that the loss may be revers-
ible. Further studies are needed to 
support these conclusions. 
Nutritional Factors 
Cross-sectional studies and a lim-
ited number of small prospective 
studies have examined the impact of 
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nutrition on bone mass in premeno-
pausal women. Although dietary ef-
fects have been the focus of numer-
ous studies of postmenopausal 
osteoporosis, they are often second-
ary measures in premenopausal stud-
ies. For example, the effect of cal-
cium intake on bone mass might be 
studied when calcium supplementa-
tion is provided during an exercise in-
tervention or a dieting program. As 
for all studies based on dietary histo-
ries, these studies are limited by re-
caU bias and extrapolation of short-
term data on food consumption. 
Calcium. Ramsdale et al72 exam-
ined the relationship between BMD 
and cal dum intake in 56 healthy pre-
menopausal women aged 21 to 4 7 
years. Statistically significant corre-
lations were found between calcium 
intake and BMD at 3 femoral sites 
(neck: r= 0.41; Ward's triangle: 
r=0.40; and trochanter: r==0.47; 
P<.OOl) and at the spine (r=0.27; 
P<.05). 72 A cross-sectional study by 
Teegarden et aF3 showed a more 
complex relationship between bone 
mass and nutrient intake. Dietary in-
take was assessed from food fre-
quency interviews in 215 white 
women aged 18 to 31 years re-
cruited for an exercise intervention 
study. The statistical model indi-
cated that adequate intakes of cal-
cium, protein, and phosphorus were 
all required for significant bone den-
sity changes to occur. 
Prospective studies have shown 
different findings in cohorts of dif-
ferent ages. A cohort studyo-t of 1.'56 
healthy white college students fol-
lowed for up to 5 years found an in-
crease of 5.9% in lumbar spinal 
BMD. Spinal BMD showed a weak 
positive correlation \vith calcium in-
take that was not statistically sig-
nificant; however, a modest but sta-
tistically significant correlation was 
seen with the calcium-protein ratio 
(r=0.20; P=.02). Citron et al74 ex-
amined the effect of calcium intake 
on spinal and radial BMD in a 4-year 
prospective study of 41 older pre-
menopausal women, aged 38 to 42 
years at baseline. Spinal bone mass 
declined -0.86%±0.15% per year 
(P<.OOl); the rate of decline was not 
attenuated by calcium intake. 
Thus, several cross-sectional and 
prospective studies have not shown 
a statistically significant association 
between BMD and calcium intake 
alone. However, calcium intake ana-
lyzed in conjunction with other nu-
trients seems to be a better predictor 
of spinal BMD in some studies. 
Protein. Cooper et aF5 studied the 
re1ationship of 6 key nutrients to 
axial and appendicular BMD in a 
cross-sectional, population-based 
study of premenopausal and post-
menopausal women based on a 
7 -day dietary record. ln the analy-
sis of72 premenopausal women, sta-
tistically significant positive asso-
ciations were found between protein 
intake and BMD in the proximal fe-
mur and distal radius; these asso-
ciations remained statistically sig-
nificant after BMD values were 
adjusted for age, weight, and physi-
cal activity. Acljusted BMD values 
were not associated with calcium 
and phosphorus intake. The 4 pre-
menopausal women who had a his-
tory of fractures at the hip, distal 
forearm, or spine had significantly 
lower intakes of protein and phos-
phorus and borderline lower in-
takes of calcium relative to other pre-
menopausal women. These results 
suggest that protein intake may be 
an important determinant of bone 
mass in premenopausal women. 
Dieting and Weight Cycling. The 
effect of voluntary weight loss on 
BMD has been studied in several set-
tings. Two small prospective studies 
of obese premenopausal patients par-
ticipating in physician-supervised 
weight loss interventions, including 
phases of very-low-calorie dieting, 
demonstrated small but statistically 
significant decreases in bone min-
eral content at the distal radius76 and 
hip77 after 8 to 36 months of follow-
up. A randomized clinical triaF3 ex-
amined bone mass in 236 healthy pre-
menopausal women aged 44 to 50 
years recmited from the community 
to participate in a lifestyle interven-
tion program for weight loss (di-
etary behavior modification and ex~ 
ercise recommendations). After 18 
months of participation, the inter-
vention group (n== 115) had lost 
3.2±4.7 kg vs a weight gain of 
0.42±3.6 kg in controls (n= 121). The 
annual rate of hip BMD loss was sig-
nificantly higher in the intervention 
group vs controls (0.81%± 1.3% loss 
vs 0.42%±1.1% loss; P<.OOl), de-
spite the fact that intake of dietary cal-
cium and ca1cium supplements in-
creased in the intervention group but 
decreased in controls. In contrast, 
Shapses et aF9 reported that lumbar 
spinal BMD increased by l. 7% from 
baseline in premenopausal obese 
women participating in a moderate 
weight loss plan with calcium supple-
mentation (1000 rng/d) (n= 14). No 
significant change in lumbar spinal 
BMD was seen in dieters who did not 
receive calcium supplementation 
(n= 14) or in controls who main-
tained their body weight (n= 10). 
Subtler degrees of eating re-
straint may also affect bone mass. Van 
Loan and Keim80 measured signifi-
cantly lovver bone mineral content in 
women who had high scores on a cog-
nitive eating restraint questionnaire 
compared v.rith women who had low 
cognitive eating restraint scores. This 
effect was seen only in women who 
weighed less than 71 kg. Menstrual 
and hormonal differences were not as-
sessed. Participants with high cogni-
tive eating restraint scores reported 
higher numbers of lifetime weight loss 
cyde..s (episode.." of weight loss> 2.25 
kg). A cross-sectional study81 of 169 
premenopausal women aged 29 to 46 
years showed lower lumbar spinal 
BMD (-0.062 g/cm2 vs controls; 
P= .Ol) in participants who reported 
a history of weight cycling (weight 
loss of at least 5 kg, followed by re-
gain of at least 50% of the loss). 
Thus, small degrees of bone loss 
have been observed in obese pa-
tients on very-low-calorie diets. Re-
sults of 2 cross-sectional studies sug-
gested that a high level of eating 
restraint and a history of repeated 
weight loss followed by regain may 
be associated with slightly lower 
bone mass. 
Physical Activity 
Attempts to analyze the effect of physi-
cal activity on bone mass have been 
hampered by methodological prob-
lems in exercise intervention stud-
ies. These studies show wide varia-
tion in interventions and outcome 
measures, small effect sizes, fre-
quent high dropout rates, and vari-
able compliance with test or control 
regimens. Wallace and Cummingn re-
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cently published a systematic review 
of randomized trials of the effect of ex-
ercise on bone mass in premeno-
pausal and postmenopausal women 
published between 1966 and 1997. 
Theyincluded8 randomized trials of 
premenopausal women; pooled re-
sults of these studies showed 1.5% 
(95% Cl, 0.6%-2.4%) less bone loss 
per year in the lumbar spine after im-
pact exercise (n= 143; 73 exercisers 
and 70 controls) and 1.2% (95% CI, 
0.7%-1.7%) less loss after nonim-
pact exercise (n=203; 95 exercisers 
and 108 controls). At the femoral 
neck, impact exercise was associated 
with 0.9% (95% CI, -0.2% to 2.0%) 
less bone loss, which approached sta-
tistical significance (n= 143; 73 exer-
cisers and 70 controls). There were 
insufficient data to analyze the effect 
of nonimpact exercise on bone mass 
at the femoral neck. 
Two sn.tdies83•84 published since 
the previously mentioned system-
atic review82 have shown statisti-
cally significant increases in BMD 
from baseline in premenopausal 
women with high levels of physical 
activity; however, neither of these 
studies showed statistically signifi-
cant differences in BMD in physi-
cally active women compared with 
controls. Two earlier randomized 
controlled trials85•86 showed statis-
tically significant increases in lum-
bar spinal BMD in women who par-
ticipated in exercise interventions 
compared with controls; all partici-
pants took a calcium supplement 
throughout both of these trials. Rel-
evant prospective studies~'3-87 of ex-
ercise are summarized in Table 2. 
Disease Factors 
Anorexia Nervosa and Associated 
Eating Disorders. Low bone mass is 
highly prevalent in patients with 
chronic anorexia nervosa (AN), es-
pecially those with the binge-eating/ 
purging subtype.83 In a cohort analy-
sis of 130 women with AN recruited 
from the community, Grinspoon et 
aF19 found that 92% of participants 
met the World Health Organiza-
tion criteria for osteopenia (BMD re-
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duced by "= !.0 SD) and that 38% 
met the criteria for osteoporosis 
(BMD reduced by 2':2.5 SD) at 1 or 
more skeletal sites. Weight was a sig-
nificant independent predictor of 
BMD at all skeletal sites; age at men-
arche and time since last menstrual 
period were significant predictors of 
spinal BMD. Undernutrition, hy-
poestrogenism, and possibly endog-
enous cortisol excess are mecha-
nisms for accelerated bone loss in 
these patients. Bone loss has the po-
tential to be most severe in chronic 
AN "vhen onset of disease is before 
attainment of peak bone mass. 90 
Other Diseases. A recent system-
atic review91 classified the follow-
ing disease states as high risk (rela-
tive risk ?:2) for fracture related to 
bone mass loss in predominantly 
postmenopausal women: primary 
hyperparathyroidism, type l diabe-
tes mellitus, AN, gastrectomy, per-
nicious anemia, and previous osteo-
porotic fracture. Moderate-risk 
diseases (relative risk of fracture l-2) 
included hyperthyroidism, diabe-
tes mellitus (type 2 or not speci-
fied), and rheumatoid arthritis. 
Accelerated bone loss may be as-
sociated with endocrine diseases that 
lead to hypoe...;;trogenism (eg, hyper-
prolactinemia92 and Sheehan 
syndrome). Disease...;; for which glu-
cocorticoid therapy is commonly pre-
scribed (eg, collagen vascular dis-
eases93 and cystic fibrosis 94) and 
conditions causing high endoge-
nous levels of glucocorticoids (eg, 
Cushing's syndrome) may be associ-
ated with premature bone loss. Mal-
absorption syndromes, inflamma-
tory bowel disease, and lactose 
intolerance95 can affect bone health in 
part by altering calcium and vitamin 
D absorption and intake. A recent 
population-based study96 of 322 
women \'irith a history of major de-
pression compared with 644 con-
trols showed that a lifetime history of 
major depression may be associated 
v.ith earlier transition to perimeno-
pause and ils associated hypoe...;;tro-
genic state, which could potentially 
lead to premature bone loss. A Na-
tional Institutes of Health-spon-
sored clinical trial97 is currently ex-
amining whether premenopausal 
women aged 21 to 45 years with ma-
jor depression lose bone mass at a 
faster rate than women V'lithout de-
pression and whether alendronate 
therapy can preserve bone mass in 
premenopausal women with major 
depression and osteoporosis. 
Medications 
Glucocorticoids. A meta-analysis98 of 
56 cross~sectionai studies and 10 lon-
gitudinal studies (a total of289l cor-
ticosteroid users, 71.5% women, av-
erage age of55.2 years, age range and 
menopausal status not specified) con-
cluded that oral doses of predniso-
lone greater than 5 mg/d or an equiva-
lent led to a reduction in BMD and a 
rapid increase in fracture risk as early 
as 3 to 6 months after initiation of 
therapy. As discussed in this analy-
sis, the increased fracture risk seems 
to be primarily due to a decline in 
bone density, but it is probably also 
due to a deterioration in bone qual-
ity. The decline in quality is evi-
denced by higher fracture rates than 
expected based on bone density 
changes alone in patients vvith cor-
ticosteroid-induced osteoporosis. 
Prolonged use of inhaled corticoste-
roids may also contribute to bone 
loss.99,100 Long-term corticosteroid use 
can cause a decline in muscle mass, 
which could potentially increase fall 
risk. Although the American Col-
lege of Rheumatology has pub-
lished guidelines for BMD monitor-
ing and preventive management in 
patients receiving long-term cortico~ 
steroid therapy, 101 many patients tak-
ing chronic exogenous corticoste-
roids do not receive preventive 
therapy for bone loss. 102 
Other Medications. Although long-
term thyroid supplementation has 
been associated with significant os-
teopenia in cross-sectional stud-
ies,103 a recent systematic review91 of 
cohort studies and case-control stud-
ies and a large cohort study'H of post-
menopausal white women did not in-
dicate an independent association 
with fracture risk In the latter study, 
current use of anticonvulsant dmgs 
was associated with increased hip 
fracture risk in an age-adjusted model 
(relative risk, 2.8; 95% Cl, !.2-6.3), 
although a previous analysisHH did not 
show an association between use of 
anticonvulsant drugs and lower ap-
pendicular bone mass. A meta-
analysis105 of 9 cross-sectional stud-
ies of long-term oral anticoagulant 
exposure found a modest negative as-
sociation v..rith bone density in the ul-
tradistal radius but no significant as-
sociation wi.th bone density in the 
distal radius, spine, or hip. 
Smoking 
Two meta-analyses106) 07 since 1997 
have reported statistically signifi-
cantly lowerBMD at the hip in long-
term smokers compared with non-
smokers. Smoking may exert its 
effect on bone by altering calcium 
and vitamin D metabolism. 108•109 
CLINICAL OUTCOMES 
Osteoporosis itself is clinically si-
lent; the disorder has clinical and 
public health importance only be-
cause it increases the risk of dis-
abling osteoporotic fractures. 110 
These outcomes are well studied in 
postmenopausal women. Although 
certain high-risk young adults may 
have BMD in the osteoporotic range, 
these patients have a low fall risk and 
greater muscle strength and dexter-
ity to protect themselves from 
higher-impact falls. How often, and 
how early, do complications occur 
in premenopausal patients? Imme-
diate and long-term clinical out-
comes should be considered. 
Immediate Clinical Outcomes 
Premenopausal osteoporotic frac-
tures are rare; however, early fragil-
ity fractures have been docu-
mented. Tn a descriptive study of 52 
consecutive premenopausal women 
aged 20 to 51 years referred to an out-
patient rheumatology clinic primar-
ily for osteoporosis management, 
Peris et aP8 found 15 patients (29%) 
with vertebral fractures and 12 with 
previous peripheral fractures. 
Low bone mass has been asso-
ciated with an increased incidence of 
stress fractures in female athletes111 
and military recruits. 1 u Certain oc-
cupational groups, such as balleri-
nas, are at increased risk of delayed 
menarche and hypothalamic amen-
orrhea leading to osteopenia and 
stress fractures. 113 A survey of 75 
dancers found that 61% (n=46) re-
ported a history of fracture, and 69% 
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of the fractures described were stress 
fractures. 1H Early stress fracturesm 
and vertebral fractures116 were docu-
mented in case series of patients \\-'i.th 
AN. A retrospective, population-
based cohort study117 assessed long-
tenn fracture risk in 208 patients with 
AN followed for a total of 2689 per-
son-years. Forty-five patients sus-
tained 88 fractures; the cumulative in-
cidence of any fracture 40 years after 
the diagnosis of AN was 57%. Frac-
tures of the hip, spine, and forearm 
occurred long after disease onset (av-
erage, 24-38 years after diagnosis). 
Adolescent idiopathic scoliosis 
has been associated with persistent os-
teopenia in a small cohortstudyl18 and 
with low body mass index due to pre-
sumed disordered eating in a cross-
sectionalstudy119 of 44youngwomen. 
A 24% prevalence of scoliosis wa...:.; re-
ported in an early study of young bal-
let dancers114 ; this value is substan-
tially higher than the 2% prevalence 
of scoliosis reported in school-aged 
children and adolescents. 120·121 
Late Clinical Outcomes 
Retrospective data from postmeno-
pausal studies3•122-125 suggest that 
fractures in early adulthood may pre-
dict fractures in the perimeno-
pausal and postmenopausal period 
(Table 3). A recent report from the 
Study of Osteoporotic Fractures co-
hort of 9086 white women aged 65 
years and older indicated that pre-
menopausal fracture is an indepen-
dent risk factor for postmeno-
pausal fracture. 122 For women with 
a history of premenopausal frac-
ture, the hazard ratio of fractures of 
all types during 12 years of fol-
low-up was 1.25 (95% CI, 1.03-
1.50) after adjustment for age, BMD, 
body mass index, use of corticoste-
roid and anticonvulsant medica-
tions, number of falls, and mater-
nal fracture history. This effect 
persisted after stratification by es-
trogen use, propensity to fracture, 
and maternal fracture history. Simi-
larly, a large retrospective, popula-
tion-based study by Honkanen et aP 
found that a history of any fracture 
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at ages 20 to 34 years was associ-
ated with an increased risk of frac-
ture at ages 35 to 57 years (hazard 
ratio, !.9; 95% CI, !.6-2.3). 
In summary, descriptive stud-
ies have shown low bone mass and a 
higher incidence of stress fractures in 
premenopausal women with certain 
disease states associated with pro-
longed amenorrhea, nutritional dep-
rivation, or excessive exercise. Pre-
menopausal fragility fractures are rare; 
however, premenopausal fractures of 
any type are an independent predic-
tor of postmenopausal fractures. 
MANAGEMENT 
Treatment Issues 
Early treatment interventions have 
been studied in premenopausal pa-
tients with secondary osteoporosis 
from a variety of causes. A Cochrane 
Revi.ew126 assessed the efficacy ofbis-
phosphonates for the prevention and 
treatment of corticosteroid-induced 
osteoporosis. This systematic re-
view included l3 controlled clinical 
trials of842adultsolder than !Syears, 
most of whom were taking chronic 
corticosteroids for collagen vascular 
diseases (especially rheumatoid ar-
thritis and lupu..<>), asthma, or chronic 
obstructive pulmonary disease. The 
weighted mean difference in BMD be-
t\veen the treatment and placebo 
groups was 4 .3°k (95% CI, 2. 7%-
5.9%) at the lumbar spine and 2.1% 
(95% Cl, 0.01 %-3.8%) at the fem-
oral neck. Efficacy regarding frac-
ture prevention could not be deter-
mined. Currently, treatment trials are 
under way examining the efficacy of 
bisphosphonates in preventing or 
treating bone loss in premenopausal 
women with premature ovarian fail-
ure due to chemotherapy for breast 
cancer, in patients ·with cystic fibro-
sis, and in children with idiopathic ju-
venile osteoporosis.97 
A randomized controlled trial bv 
Klibanski et aP 27 (n=48) and a r~­
cent prospective cohort study by 
Golden et aP 28 (n=50) showed that 
estrogen-progestin replacement 
therapy did not prevent progressive 
bone loss in premenopausal patients 
with AN. Raloxifene therapy was 
found to prevent gonadotropin-
releasing hormone-agonist-related 
bone loss in a single-blind, random-
ized controlled triaP 29 of 100 pre-
menopausal women receiving treat-
ment for uterine leiomyomas. 
Safety ofbone-protective agents 
for women of reproductive age must 
be considered. For example, bisphos-
phonates have a category Crating for 
safety in pregnancy, based on toxic ef-
fects at parturition in d1e rat model. 130 
Bisphosphonates have been shown to 
pass through the rat placenta and ac-
cumulate in fetuses.m These agents 
may be stored in bone for long peri-
ods, and the long-term implications 
for women of childbearing age are un-
certain. Potential risks and lack of ef-
ficacy data on fracture risk reduc-
tion in premenopausal women must 
be weighed against the proven effi-
cacy ofbisphosphonates to decrease 
fractures in postmenopausal wom-
en.132·133 Bisphosphonate use should 
be limited in premenopausal women 
until further research clarifies its safety 
and efficacy. 
Screening Issues 
Although some clinical outcomes may 
occur early, screening for premeno-
pausal osteoporosis in the general 
population is not feasible. The US Pre-
ventive Services Task Force134 con-
siders screening in women younger 
than 60 years a grade C recommen-
dation, that is, although the Task 
Force found at least fair evidence that 
this process can improve health out-
comes (prevent fractures), it con-
cluded that the balance of benefits and 
harms is too close to justify a general 
recommendation. The National Os-
teoporosis Foundation mentions that 
current data are insufficient to for-
mulate specific recommendations for 
premenopausal women, nonwhite 
women, or men. However, the Na-
tional Osteoporosis Foundation 135 
recommends that risk factors be used 
on an individual basis to determine 
the need for bone density testing and 
treatment and that all people should 
follow universal recommendations for 
bone health. 
A case-findingstrategy could be 
considered for premenopausal 
women with disease conditions 
known to be strongly associated with 
accelerated bone loss. Early detec-
tion of osteoporosis could allow in-
terventions at an age when appropri-
ate measures could maximize bone 
accrual and minimize loss over a 
much longer period before meno-
pause. Some interventions are more 
likely to be effective in younger wom-
en; for example, more strenuous 
physical activity can be recom-
mended to younger patients, and they 
may be more likely to comply with 
exercise prescriptions than perimeno-
pausal and postmenopausal women. 
Moreover, older patients are more 
likely to have already sustained frac-
tures or to have comorbid condi-
tions that could limit their ability to 
comply with an exercise regimen. 
However, advantages of early 
detection must be weighed against po-
tential harms, which include treat-
ment-associated morbidity, inappro-
priate treaunent of patients with false-
positive test results, prolonged 
psychological distress in some pa-
tients over misperceived fracture risk, 
and misallocation of resources if more 
lives could be saved or improved 
through other preventive measures. 
Existing evidence regarding the bal-
ance of benefits and harms is insuffi-
cient to allow reasonable cost-effective 
analyses of screening strategies for 
premenopausal osteoporosis. 
Guidelines 
A search of the National Guide-
lines Clearinghouse in November 
2002 revealed 8 practice guidelines 
directly relating to osteoporosis 
management. Four of these guide-
lines offer some diagnostic or treat-
ment information for premeno-
pausal patients6·101 ·D6.1 37; the fifth 
mentions that its prevention guide-
lines apply to adults of all ages.U8 
The 2001 update of the American 
College of Rheumatology Recom-
mendations for the Prevention and 
Treatment of Glucocorticoid-
Induced Osteoporosis mentions that 
prevention of bone loss with anti-
resorptive agents should be consid-
ered for premenopausal women re-
ceiving glucocorticoid therapy. 101 
Evidence to date does not support 
screening for osteoporosis in pre-
menopausal women in the general 
population. However, certain pa-
tient populations are at higher risk of 
accelerated bone loss at an early age; 
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a systematic method for identifying 
these patients in primary care is lack-
ing. Further research must clarify the 
relative importance of risk factors for 
early bone loss and better document 
the potential benefits and harms of 
screening before a useful approach to 
selective screening can be devel-
oped. Until then, we will rely on 
heightened knowledge of primary 
care physicians to identify young 
women who may need early bone 
health assessment and preventive in-
terventions. The evidence reviB.ved in 
this article supports consideration of 
risk assessment and bone densitvtest-
ing for premenopausal warner{ with 
the following conditions: frequent or 
prolonged use of corticosteroid medi-
cations (2::5 mg of oral prednisolone 
or the equivalent per day for 2::3 
months), past or current AN, pro-
longed or recurrent amenorrhea, hy-
perparathyroidism, rheumatoid ar-
thritis, and hyperthyroidism. Patients 
with abnormally low bone density will 
often require additional laboratory 
workup, nutritional evaluation, or 
specialty referral. 
Future research should focus on 
prevention in addition to therapeu-
tic interventions. Health care practi-
tioners also need to increase patient 
education on modifiable disease fac-
tors, including optimal nutrition from 
birth, age-appropriate regular weight-
bearing exercise, smoking cessa-
tion, and minimization of environ-
mental risk factors for fracture. The 
goal should be to institute age-
appropriate interventions at a stage 
when bone quality is intact and fu-
ture loss can be minimized. 
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